Grand Pharmaceutical Group Ltd. Announces Approval for Commercialization of Innovative Demodex Blepharitis Treatment by Macao ISAF of China

Reuters

05/25

Grand Pharmaceutical Group Ltd. Announces Approval for Commercialization of Innovative Demodex Blepharitis Treatment by Macao ISAF of China

Grand Pharmaceutical Group Ltd. has announced progress in its clinical trials and product development within the ophthalmic sector. The company's Phase III clinical study in China for GPN00153 (CBT-001), a new drug aimed at treating pterygium, has completed its initial patient enrollment and dosing as of March 2024, with plans to conclude all patient enrollment and dosing by June 2025. Additionally, GPN00884, a global innovative drug designed to delay the progression of myopia in children, has achieved its first patient enrollment in a Phase I clinical study conducted in China in June 2024. Grand Pharmaceutical Group is focused on enhancing its R&D pipeline, particularly in ophthalmology, and is committed to increasing investment in innovative products and technology to address unmet clinical needs. The company advises caution, as the approval and commercialization of these products remain subject to various uncertainties.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 25, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2538114190"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2538114190\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2538114190?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-25 18:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2538114190","market":"nz","top_or_hot":-1,"title":"Grand Pharmaceutical Group Ltd. Announces Approval for Commercialization of Innovative Demodex Blepharitis Treatment by Macao ISAF of China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Grand Pharmaceutical Group Ltd. Announces Approval for Commercialization of Innovative Demodex Blepharitis Treatment by Macao ISAF of China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grand Pharmaceutical Group Ltd. has announced progress in its clinical trials and product development within the ophthalmic sector. The company's Phase III clinical study in China for GPN00153 (CBT-001), a new drug aimed at treating pterygium, has completed its initial patient enrollment and dosing as of March 2024, with plans to conclude all patient enrollment and dosing by June 2025. Additionally, GPN00884, a global innovative drug designed to delay the progression of myopia in children, has achieved its first patient enrollment in a Phase I clinical study conducted in China in June 2024. Grand Pharmaceutical Group is focused on enhancing its R&amp;D pipeline, particularly in ophthalmology, and is committed to increasing investment in innovative products and technology to address unmet clinical needs. The company advises caution, as the approval and commercialization of these products remain subject to various uncertainties.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Grand Pharmaceutical Group Ltd. Announces Approval for Commercialization of Innovative Demodex Blepharitis Treatment by Macao ISAF of China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGrand Pharmaceutical Group Ltd. Announces Approval for Commercialization of Innovative Demodex Blepharitis Treatment by Macao ISAF of China\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-25 18:21</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Grand Pharmaceutical Group Ltd. Announces Approval for Commercialization of Innovative Demodex Blepharitis Treatment by Macao ISAF of China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Grand Pharmaceutical Group Ltd. has announced progress in its clinical trials and product development within the ophthalmic sector. The company's Phase III clinical study in China for GPN00153 (CBT-001), a new drug aimed at treating pterygium, has completed its initial patient enrollment and dosing as of March 2024, with plans to conclude all patient enrollment and dosing by June 2025. Additionally, GPN00884, a global innovative drug designed to delay the progression of myopia in children, has achieved its first patient enrollment in a Phase I clinical study conducted in China in June 2024. Grand Pharmaceutical Group is focused on enhancing its R&amp;D pipeline, particularly in ophthalmology, and is committed to increasing investment in innovative products and technology to address unmet clinical needs. The company advises caution, as the approval and commercialization of these products remain subject to various uncertainties.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00512","symbol_name":"遠大醫藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250525:nNDL90mDqW:1","article_id":"2538114190","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2538114190","pubTimestamp":1748168505,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Grand Pharmaceutical Group Ltd. Announces Approval for Commercialization of Innovative Demodex Blepharitis Treatment by Macao ISAF of China. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 25, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00512":"远大医药","BK1191":"制药"},"translate_title":"远大医药集团有限公司宣布中国澳门ISAF批准创新治疗睑缘炎蠕形螨的商业化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":0.9},"content_text":"Grand Pharmaceutical Group Ltd. Announces Approval for Commercialization of Innovative Demodex Blepharitis Treatment by Macao ISAF of China\n    \n\n        Grand Pharmaceutical Group Ltd. has announced progress in its clinical trials and product development within the ophthalmic sector. The company's Phase III clinical study in China for GPN00153 (CBT-001), a new drug aimed at treating pterygium, has completed its initial patient enrollment and dosing as of March 2024, with plans to conclude all patient enrollment and dosing by June 2025. Additionally, GPN00884, a global innovative drug designed to delay the progression of myopia in children, has achieved its first patient enrollment in a Phase I clinical study conducted in China in June 2024. Grand Pharmaceutical Group is focused on enhancing its R&D pipeline, particularly in ophthalmology, and is committed to increasing investment in innovative products and technology to address unmet clinical needs. The company advises caution, as the approval and commercialization of these products remain subject to various uncertainties.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grand Pharmaceutical Group Ltd. published the original content used to generate this news brief on May 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}